06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.56
−0.70%Aug 24, 2026, 23:19 UTC
Antengene announced that its Phase I ATTRACT study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B-cell related autoimmune diseases, received approval from the Australian Human Research Ethics Committee and completed the Clinical Trial Notification submission to the Therapeutic Goods Administration.
Source:Aug 21, 2026, 10:36 UTC
Antengene Corporation reported interim results for the six months ended June 30, 2026, with revenue of RMB 513 million, up 865% year-over-year, and a net profit of RMB 216 million, reversing a loss of RMB 76.378 million in the prior-year period.
Source:Jul 13, 2026, 04:02 UTC
Antengene Corporation received a $60 million upfront payment from UCB under a milestone agreement for ATG-201.